Ahmed M. Sayed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahmed M. Sayed has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Nguyen Tien Huy
Institute of Research and Development Duy Tan University Da Nang Vietnam
7 shared publications - Abdelrahman S. Mayhoub
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt
2 shared publications Ehab A. Salama
Affiliations Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America
2 shared publications- Gehad Mohamed Tawfik
Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 shared publications - Kenji Hirayama
School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan
2 shared publications Mohamed Hagras
Affiliation Department of Pharmaceutical Organic Chemistry, College of Pharmacy, Al-Azhar University, Cairo, Egypt
2 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0355495
Expedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis
FDA expedited programs are intended to facilitate development and review for therapies addressing serious conditions with unmet medical need, but their use may depend on whether the evidentiary package is compatible with regulatory acceleration. We compared FDA original approvals in oncology and neurology from 2015 to 2024 to evaluate whether differences in approval timing reflected expedited pathway portfolio intensity, pivotal evidence architecture, or alignment between the two. We conducted a retrospective comparative cohort study of 195 original FDA approvals, including 136 oncology products and 59 neurology products. Product-level regulatory data were curated from FDA approval materials. Pivotal or registrational trials supporting first approval were identified from FDA labels and review documents and enriched through exact National Clinical Trial identifier matching to AACT. The final evidence dataset included 221 curated product–trial links. Regulatory pathway-portfolio intensity was summarized using a Regulatory Bundling Index incorporating Fast Track, Breakthrough Therapy designation, Priority Review, Accelerated Approval, and Orphan designation. Outcomes included regulatory approval time, clinical development time, total time to approval, and pivotal evidence architecture. Oncology products had higher pathway intensity than neurology products, with median Regulatory Bundling Index 3 [IQR, 2–4] versus 2 [IQR, 0–3] (p < 0.001). Neurology products had longer regulatory approval time than oncology products: 362 days [IQR, 245–366] versus 234 days [IQR, 182–329] (p < 0.001). In contrast, clinical development time and total time to approval did not differ significantly. Neurology pivotal evidence was more often randomized, masked, and late phase, while oncology evidence was more often single group. Trial enrollment did not differ significantly. In exploratory counterfactual analyses, increasing neurology pathway intensity to the oncology median was associated with a median predicted review-time reduction of 37.8 days. Differences in FDA approval timing between oncology and neurology appear to reflect both pathway configuration and pivotal evidence architecture. These findings support a pathway-evidence alignment framework rather than a simple model in which more expedited designations alone explain faster approval.
- 27 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0355495
Open AccessExpedited pathway portfolios, trial complexity, and FDA approval timelines in oncology and neurology: A comparative analysis
FDA expedited programs are intended to facilitate development and review for therapies addressing serious conditions with unmet medical need, but their use may depend on whether the evidentiary package is compatible with regulatory acceleration. We compared FDA original approvals in oncology and neurology from 2015 to 2024 to evaluate whether differences in approval timing reflected expedited pathway portfolio intensity, pivotal evidence architecture, or alignment between the two. We conducted a retrospective comparative cohort study of 195 original FDA approvals, including 136 oncology products and 59 neurology products. Product-level regulatory data were curated from FDA approval materials. Pivotal or registrational trials supporting first approval were identified from FDA labels and review documents and enriched through exact National Clinical Trial identifier matching to AACT. The final evidence dataset included 221 curated product–trial links. Regulatory pathway-portfolio intensity was summarized using a Regulatory Bundling Index incorporating Fast Track, Breakthrough Therapy designation, Priority Review, Accelerated Approval, and Orphan designation. Outcomes included regulatory approval time, clinical development time, total time to approval, and pivotal evidence architecture. Oncology products had higher pathway intensity than neurology products, with median Regulatory Bundling Index 3 [IQR, 2–4] versus 2 [IQR, 0–3] (p < 0.001). Neurology products had longer regulatory approval time than oncology products: 362 days [IQR, 245–366] versus 234 days [IQR, 182–329] (p < 0.001). In contrast, clinical development time and total time to approval did not differ significantly. Neurology pivotal evidence was more often randomized, masked, and late phase, while oncology evidence was more often single group. Trial enrollment did not differ significantly. In exploratory counterfactual analyses, increasing neurology pathway intensity to the oncology median was associated with a median predicted review-time reduction of 37.8 days. Differences in FDA approval timing between oncology and neurology appear to reflect both pathway configuration and pivotal evidence architecture. These findings support a pathway-evidence alignment framework rather than a simple model in which more expedited designations alone explain faster approval.
- Open Access
Operational complexity predicts selective non-dissemination within pharmaceutical sponsor portfolios: a retrospective cohort study
Background: Incomplete dissemination of clinical trial results remains an important challenge for research transparency and evidence synthesis. Although prior studies have quantified the overall extent of non-dissemination, less is known about whether trial characteristics observable at registration are associated with subsequent dissemination within sponsor portfolios. Methods and findings: We conducted a retrospective cohort study of 17,537 completed interventional clinical trials registered on ClinicalTrials.gov between 2007 and 2024 across the 20 largest global pharmaceutical companies. We developed the Operational Complexity Index (OCI), a composite measure derived from planned enrollment, facility count, and geographic scope, and examined its association with trial dissemination using multivariable logistic regression and time-to-event analyses. Higher OCI was associated with greater odds of dissemination (adjusted odds ratio [aOR] = 2.40, 95% CI 2.23–2.60; p < 0.001), with dissemination increasing from 47% in the lowest OCI decile to 95% in the highest. Higher operational complexity was also associated with earlier dissemination; over a 1,095-day horizon, high-OCI trials were disseminated a mean of 310.88 days earlier than low-OCI trials (RMST difference, 310.88 days; 95% CI 300.59–320.96; p < 0.001). This pattern was observed across sponsors, clinical phases, and therapeutic areas. In predictive analyses using registration-time variables, the structural model achieved a cross- validated AUC of 0.816 and a holdout AUC of 0.814, whereas the full model, including sponsor identity, achieved a cross-validated AUC of 0.858 and a holdout AUC of 0.857. Using benchmark phase-based costing assumptions, the 5,019 non-disseminated trials corresponded to an estimated US$10.94–15.26 billion in sunk research investment. Conclusions: Among trials conducted by the 20 largest pharmaceutical sponsors, greater operational complexity at registration was associated with a higher likelihood of dissemination and earlier dissemination. These findings suggest that aggregate sponsor-level transparency metrics may mask important heterogeneity within sponsor portfolios. Future work should assess whether registration-time trial characteristics can help identify trial subgroups at higher risk of non-dissemination. AUTHOR SUMMARY: Why was this study done?: Incomplete dissemination of clinical trial results reduces the completeness of the medical evidence base and the public value of research participation. Previous studies have described overall rates of trial non-dissemination, but less is known about whether dissemination varies systematically across different types of trials within sponsor portfolios. We examined whether trial characteristics available at registration were associated with later dissemination of results among large pharmaceutical sponsors. What did the researchers do and find?: We analyzed 17,537 completed interventional clinical trials sponsored by the 20 largest pharmaceutical companies and registered on ClinicalTrials.gov between 2007 and 2024. We developed an Operational Complexity Index (OCI) based on planned enrollment, number of facilities, and geographic scope to measure trial operational scale at registration. Higher OCI was associated with a greater likelihood of dissemination and earlier dissemination. Dissemination ranged from 47% in the lowest OCI decile to 95% in the highest. This pattern was observed across sponsor portfolios, clinical phases, and therapeutic areas, with an average within-sponsor dissemination gap of 40 percentage points between lower- and higher-complexity trials. In manual validation of 344 sampled trials, the automated dissemination-classification pipeline achieved 92.1% accuracy. Using benchmark phase-based costing assumptions, the 5,019 non-disseminated trials corresponded to an estimated US$10.9–15.3 billion in sunk research investment. What do these findings mean?: Dissemination was not uniform across trial types within sponsor portfolios; trials with lower operational complexity were less likely to be disseminated than trials with higher operational complexity. Aggregate sponsor-level transparency measures may therefore miss important differences within portfolios. Registration-time trial characteristics showed predictive signal for non-dissemination, but whether such information could support monitoring strategies would require prospective validation. More complete dissemination of trial results would strengthen the scientific record and improve the public value of clinical research.
Open AccessOperational complexity predicts selective non-dissemination within pharmaceutical sponsor portfolios: a retrospective cohort study
Background: Incomplete dissemination of clinical trial results remains an important challenge for research transparency and evidence synthesis. Although prior studies have quantified the overall extent of non-dissemination, less is known about whether trial characteristics observable at registration are associated with subsequent dissemination within sponsor portfolios. Methods and findings: We conducted a retrospective cohort study of 17,537 completed interventional clinical trials registered on ClinicalTrials.gov between 2007 and 2024 across the 20 largest global pharmaceutical companies. We developed the Operational Complexity Index (OCI), a composite measure derived from planned enrollment, facility count, and geographic scope, and examined its association with trial dissemination using multivariable logistic regression and time-to-event analyses. Higher OCI was associated with greater odds of dissemination (adjusted odds ratio [aOR] = 2.40, 95% CI 2.23–2.60; p < 0.001), with dissemination increasing from 47% in the lowest OCI decile to 95% in the highest. Higher operational complexity was also associated with earlier dissemination; over a 1,095-day horizon, high-OCI trials were disseminated a mean of 310.88 days earlier than low-OCI trials (RMST difference, 310.88 days; 95% CI 300.59–320.96; p < 0.001). This pattern was observed across sponsors, clinical phases, and therapeutic areas. In predictive analyses using registration-time variables, the structural model achieved a cross- validated AUC of 0.816 and a holdout AUC of 0.814, whereas the full model, including sponsor identity, achieved a cross-validated AUC of 0.858 and a holdout AUC of 0.857. Using benchmark phase-based costing assumptions, the 5,019 non-disseminated trials corresponded to an estimated US$10.94–15.26 billion in sunk research investment. Conclusions: Among trials conducted by the 20 largest pharmaceutical sponsors, greater operational complexity at registration was associated with a higher likelihood of dissemination and earlier dissemination. These findings suggest that aggregate sponsor-level transparency metrics may mask important heterogeneity within sponsor portfolios. Future work should assess whether registration-time trial characteristics can help identify trial subgroups at higher risk of non-dissemination. AUTHOR SUMMARY: Why was this study done?: Incomplete dissemination of clinical trial results reduces the completeness of the medical evidence base and the public value of research participation. Previous studies have described overall rates of trial non-dissemination, but less is known about whether dissemination varies systematically across different types of trials within sponsor portfolios. We examined whether trial characteristics available at registration were associated with later dissemination of results among large pharmaceutical sponsors. What did the researchers do and find?: We analyzed 17,537 completed interventional clinical trials sponsored by the 20 largest pharmaceutical companies and registered on ClinicalTrials.gov between 2007 and 2024. We developed an Operational Complexity Index (OCI) based on planned enrollment, number of facilities, and geographic scope to measure trial operational scale at registration. Higher OCI was associated with a greater likelihood of dissemination and earlier dissemination. Dissemination ranged from 47% in the lowest OCI decile to 95% in the highest. This pattern was observed across sponsor portfolios, clinical phases, and therapeutic areas, with an average within-sponsor dissemination gap of 40 percentage points between lower- and higher-complexity trials. In manual validation of 344 sampled trials, the automated dissemination-classification pipeline achieved 92.1% accuracy. Using benchmark phase-based costing assumptions, the 5,019 non-disseminated trials corresponded to an estimated US$10.9–15.3 billion in sunk research investment. What do these findings mean?: Dissemination was not uniform across trial types within sponsor portfolios; trials with lower operational complexity were less likely to be disseminated than trials with higher operational complexity. Aggregate sponsor-level transparency measures may therefore miss important differences within portfolios. Registration-time trial characteristics showed predictive signal for non-dissemination, but whether such information could support monitoring strategies would require prospective validation. More complete dissemination of trial results would strengthen the scientific record and improve the public value of clinical research.
- Open Access
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Regulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.
- 13 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessRegulatory alignment in FDA expedited pathways for infectious diseases: a decadal review with predictive modeling insights
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.
- Open Access
- 25 March 2025
- Published by Springer Nature in The Egyptian Journal of Otolaryngology
- Vol. 41 (1) , 1-15
Outcomes and complication rates of different materials used for nasal dorsal augmentation in septorhinoplasty: a systematic review and meta-analysis
Autologous materials and alloplastic implants are commonly used in dorsal augmentation of septorhinoplasty (SRP). So far, there is no satisfactory evidence to ascertain the safest, efficient, and superior aesthetic outcomes among different materials. Objective This systematic review and meta-analysis (SR/MA) aim to compare the outcomes and complication rates of various materials used for nasal dorsal augmentation in SRP. Methods A comprehensive search was conducted in PubMed, Embase, and Cochrane Library databases. Studies were included based on predefined criteria, and data were extracted on outcomes and complications. Statistical analyses were performed to compare the materials. Thirteen electronic databases were searched from inception through December 2018 and a manual search in October 2019. Results A total of 280 eligible studies were included, of which 165 articles were included in MA. Alloplastic expanded polytetrafluoroethylene (e-PTFE) showed the highest graft scores across most outcomes with low complication rates. Silicone implants had a high success rate but slightly higher complications. Autologous materials such as bone and cartilage presented higher complication rates and donor site morbidity. Conclusion e-PTFE appears to be the superior material for nasal dorsal augmentation due to its high patient satisfaction and low complication rates. Future studies should focus on long-term outcomes and racial differences in material performance. Trial registration PROSPERO CRD42019119165.
- 25 March 2025
- Published by Springer Nature in The Egyptian Journal of Otolaryngology
- Vol. 41 (1) , 1-15
Open AccessOutcomes and complication rates of different materials used for nasal dorsal augmentation in septorhinoplasty: a systematic review and meta-analysis
Autologous materials and alloplastic implants are commonly used in dorsal augmentation of septorhinoplasty (SRP). So far, there is no satisfactory evidence to ascertain the safest, efficient, and superior aesthetic outcomes among different materials. Objective This systematic review and meta-analysis (SR/MA) aim to compare the outcomes and complication rates of various materials used for nasal dorsal augmentation in SRP. Methods A comprehensive search was conducted in PubMed, Embase, and Cochrane Library databases. Studies were included based on predefined criteria, and data were extracted on outcomes and complications. Statistical analyses were performed to compare the materials. Thirteen electronic databases were searched from inception through December 2018 and a manual search in October 2019. Results A total of 280 eligible studies were included, of which 165 articles were included in MA. Alloplastic expanded polytetrafluoroethylene (e-PTFE) showed the highest graft scores across most outcomes with low complication rates. Silicone implants had a high success rate but slightly higher complications. Autologous materials such as bone and cartilage presented higher complication rates and donor site morbidity. Conclusion e-PTFE appears to be the superior material for nasal dorsal augmentation due to its high patient satisfaction and low complication rates. Future studies should focus on long-term outcomes and racial differences in material performance. Trial registration PROSPERO CRD42019119165.
- Open Access
- 7 December 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (24) , 16404
Non-Invasive Prenatal Testing (NIPT) Implementation in Japan: A Comparison with the United Kingdom, Germany, Italy, Sweden, and Taiwan
Introduction: The Non-Invasive Prenatal Testing (NIPT) guideline was issued and applied in 2013 by the Japanese Medical Association. Since being issued, the NIPT practice in Japan still has some problems related to indication, access, cost coverage and uniformity. Therefore, our study aimed to identify the Japanese challenges of adopting NIPT into prenatal diagnosis by comparing the system and process with other countries. Method: The United Kingdom, Germany, Italy, Sweden, and Taiwan were purposefully selected for comparison. All the countries, including Japan, introduced NIPT. The literature and information searches were conducted using PubMed, SCOPUS, Google Scholar, CiNii and Google searching engine. Results: The process of NIPT in Japan was very different from the other countries. Japan is the only country that indicated NIPT for only pregnant women over 35 years old in certificated facilities and did not have a policy regarding providing information on prenatal screening and NIPT to all women. Japan also did not have a policy regarding abortion due to fetal abnormalities. The practice of NIPT guidelines is different between non-certified and certified facilities. NIPT fee was the highest in Japan and was not covered by insurance. Conclusion: Pregnant women in Japan suffered from disparities in information access, economic burden, geographic location, and practice of NIPT guidelines between the certified and the non-certified facilities. Pregnant women-centered prenatal diagnosis policy, including NIPT, should be established in Japan by learning cases from other countries.
- 7 December 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (24) , 16404
Open AccessNon-Invasive Prenatal Testing (NIPT) Implementation in Japan: A Comparison with the United Kingdom, Germany, Italy, Sweden, and Taiwan
Introduction: The Non-Invasive Prenatal Testing (NIPT) guideline was issued and applied in 2013 by the Japanese Medical Association. Since being issued, the NIPT practice in Japan still has some problems related to indication, access, cost coverage and uniformity. Therefore, our study aimed to identify the Japanese challenges of adopting NIPT into prenatal diagnosis by comparing the system and process with other countries. Method: The United Kingdom, Germany, Italy, Sweden, and Taiwan were purposefully selected for comparison. All the countries, including Japan, introduced NIPT. The literature and information searches were conducted using PubMed, SCOPUS, Google Scholar, CiNii and Google searching engine. Results: The process of NIPT in Japan was very different from the other countries. Japan is the only country that indicated NIPT for only pregnant women over 35 years old in certificated facilities and did not have a policy regarding providing information on prenatal screening and NIPT to all women. Japan also did not have a policy regarding abortion due to fetal abnormalities. The practice of NIPT guidelines is different between non-certified and certified facilities. NIPT fee was the highest in Japan and was not covered by insurance. Conclusion: Pregnant women in Japan suffered from disparities in information access, economic burden, geographic location, and practice of NIPT guidelines between the certified and the non-certified facilities. Pregnant women-centered prenatal diagnosis policy, including NIPT, should be established in Japan by learning cases from other countries.
- Open Access
- 4 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0258465
Evaluation of bisphenylthiazoles as a promising class for combating multidrug-resistant fungal infections
To minimize the intrinsic toxicity of the antibacterial agent hydrazinyloxadiazole 1, the hydrazine moiety was replaced with ethylenediamine (compound 7). This replacement generated a potent antifungal agent with no antibacterial activity. Notably, use of a 1,2-diaminocyclohexane moiety, as a conformationally-restricted isostere for ethylenediamine, potentiated the antifungal activity in both the cis and trans forms of N-(5-(2-([1,1’-biphenyl]-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl)cyclohexane-1,2-diamine (compounds 16 and 17). Both compounds 16 and 17 were void of any antibacterial activity; nonetheless, they showed equipotent antifungal activity in vitro to that of the most potent approved antifungal agent, amphotericin B. The promising antifungal effects of compounds 16 and 17 were maintained when assessed against an additional panel of 26 yeast and mold clinical isolates, including the Candida auris and C. krusei. Furthermore, compound 17 showed superior activity to amphotericin B in vitro against Candida glabrata and Cryptococcus gattii. Additionally, neither compound inhibited the normal human microbiota, and both possessed excellent safety profiles and were 16 times more tolerable than amphotericin B.
- 4 November 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (11) , e0258465
Open AccessEvaluation of bisphenylthiazoles as a promising class for combating multidrug-resistant fungal infections
To minimize the intrinsic toxicity of the antibacterial agent hydrazinyloxadiazole 1, the hydrazine moiety was replaced with ethylenediamine (compound 7). This replacement generated a potent antifungal agent with no antibacterial activity. Notably, use of a 1,2-diaminocyclohexane moiety, as a conformationally-restricted isostere for ethylenediamine, potentiated the antifungal activity in both the cis and trans forms of N-(5-(2-([1,1’-biphenyl]-4-yl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-2-yl)cyclohexane-1,2-diamine (compounds 16 and 17). Both compounds 16 and 17 were void of any antibacterial activity; nonetheless, they showed equipotent antifungal activity in vitro to that of the most potent approved antifungal agent, amphotericin B. The promising antifungal effects of compounds 16 and 17 were maintained when assessed against an additional panel of 26 yeast and mold clinical isolates, including the Candida auris and C. krusei. Furthermore, compound 17 showed superior activity to amphotericin B in vitro against Candida glabrata and Cryptococcus gattii. Additionally, neither compound inhibited the normal human microbiota, and both possessed excellent safety profiles and were 16 times more tolerable than amphotericin B.
- Open Access
- 2 November 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-11
Survey of knowledge, attitude and practice of healthcare professionals on dengue transmission, diagnosis and clinical classification
Background: To investigate the knowledge, attitudes, and practices of the healthcare professionals (HCPs) including physicians and nurses regarding dengue transmission, diagnosis and clinical classification using the warning signs of World Health Organization (WHO) 2009 classification.Results: Out of 471 respondents from three countries, 80.9% of physicians and 74% of nurses did not receive previous training regarding the dengue infection. The majority of respondents could identify the primary dengue vector (86%), while only a third of HCPs knew the biting time of dengue mosquitoes. Only half of our respondents knew about immunity induced by serotypes; Moreover, half of our participants could determine the diagnostic tests. On the other hand, about 90% of the respondents took responsibility for talking to the patients about preventive measures. Our respondents also showed wide variations in definition of warning signs listed in the WHO 2009 classification. Multivariate analysis linked the impact of different cofactors including prior training on dengue infection, type of profession, frequency of taking care of dengue patients and country on how HCPs defined these warning signs.Conclusions: This study could declare the variation in employing the warning signs listed in the WHO 2009 classification. We have figured that most of the HCPs did not take prior training on the dengue viral infection; Also, we found gaps in the knowledge regarding various topics in dengue fever. This paper recommends the gathering of efforts to establish the proper knowledge of dengue infection and the warning signs listed by the WHO.
- 2 November 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-11
Open AccessSurvey of knowledge, attitude and practice of healthcare professionals on dengue transmission, diagnosis and clinical classification
Background: To investigate the knowledge, attitudes, and practices of the healthcare professionals (HCPs) including physicians and nurses regarding dengue transmission, diagnosis and clinical classification using the warning signs of World Health Organization (WHO) 2009 classification.Results: Out of 471 respondents from three countries, 80.9% of physicians and 74% of nurses did not receive previous training regarding the dengue infection. The majority of respondents could identify the primary dengue vector (86%), while only a third of HCPs knew the biting time of dengue mosquitoes. Only half of our respondents knew about immunity induced by serotypes; Moreover, half of our participants could determine the diagnostic tests. On the other hand, about 90% of the respondents took responsibility for talking to the patients about preventive measures. Our respondents also showed wide variations in definition of warning signs listed in the WHO 2009 classification. Multivariate analysis linked the impact of different cofactors including prior training on dengue infection, type of profession, frequency of taking care of dengue patients and country on how HCPs defined these warning signs.Conclusions: This study could declare the variation in employing the warning signs listed in the WHO 2009 classification. We have figured that most of the HCPs did not take prior training on the dengue viral infection; Also, we found gaps in the knowledge regarding various topics in dengue fever. This paper recommends the gathering of efforts to establish the proper knowledge of dengue infection and the warning signs listed by the WHO.
- Open Access
- 1 November 2020
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 13 (11) , 1682-1693
Concordance of bone and non-bone specimens in microbiological diagnosis of osteomyelitis: A systematic review and meta-analysis
- 1 November 2020
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 13 (11) , 1682-1693
Open AccessConcordance of bone and non-bone specimens in microbiological diagnosis of osteomyelitis: A systematic review and meta-analysis
- 1 March 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 189, 112046
Oxadiazolylthiazoles as novel and selective antifungal agents
- 1 March 2020
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 189, 112046
Oxadiazolylthiazoles as novel and selective antifungal agents
- 1 March 2020
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 119, 26-35
Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups
- 1 March 2020
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 119, 26-35
Frequent inappropriate use of unweighted summary statistics in systematic reviews of pathogen genotypes or genogroups